Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 21:3:1-5.

Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

Katherine A Lewis  1 , Erica A Eugster
Affiliations

Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

Katherine A Lewis et al. Drug Des Devel Ther. .

Abstract

In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

Keywords: central precocious puberty; gonadotropin-releasing-hormone analogs; histrelin; implant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Appearance and size of the histrelin subcutaneous implant. Numbers on the ruler represent 1-inch markings (1 inch = 25 mm).
Figure 2
Figure 2
Appearance of typical scar seen 6 months after implantation of histrelin implant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care. 2007;37(2):50–72. - PubMed
    1. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108(1):47–54. - PubMed
    1. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB., Jr Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711–4716. - PubMed
    1. Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005;116(6):e798–802. - PubMed
    1. Dineen MK, Tierney DS, Kuzma P, Pentikis HS. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol. 2005;45(11):1245–1249. - PubMed

LinkOut - more resources